Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print XDR TB in South Africa traced to lack of drug susceptibility testing

XDR TB in South Africa traced to lack of drug susceptibility testing

October 23, 2007

In South Africa, the 2001 implementation of the World Health Organization's anti-tuberculosis program may have inadvertently helped to create a new strain of extensively drug-resistant tuberculosis (XDR TB). In a new study published in the December 1 issue of Clinical Infectious Diseases, currently available online, researchers tracked the developing drug resistance of one particular strain of Mycobacterium tuberculosis over 12 years. They found that at the time of the 2001 adoption of the DOT+ strategy for multi-drug resistant strains, the strain was already resistant to one or more of the drugs mandated by that strategy, thus allowing the strain to survive and develop resistance to additional drugs.

"The spread of a highly transmissible strain of drug-resistant tuberculosis has been facilitated by applying standard treatment regimens for susceptible and multi-drug resistant tuberculosis in the absence of drug resistance surveillance," said one of the authors, A. Willem Sturm, MD, of the University of KwaZulu-Natal's Nelson R. Mandela School of Medicine in South Africa. "Public health programs for the treatment and control of infectious diseases need to be supported by drug resistance surveillance programs."




Like all bacteria, M. tuberculosis can evolve and develop resistance to the drugs that have historically killed them. The strategy that has been used to limit the development of drug-resistant TB is to treat the patient with multiple drugs so that if one drug is ineffective, then the others will ensure the elimination of the bacteria.

Drug-resistant M. tuberculosis develops when tuberculosis patients cannot or do not comply with the medication regimen. A second line of drugs has been used to treat those infected with drug-resistant TB. This second-line medication regimen was adopted in South Africa in 2001 to treat drug-resistant TB.

Unfortunately, at least one strain of M. tuberculosis in South Africa had already developed resistance to one or more of these second-line drugs by the time they were introduced. Drug susceptibility tests would have warned doctors that the standard second-line regimen was unlikely to help the patient but was likely to lead to additional drug-resistance, but these tests were not performed or were not available. Indeed, the reduced efficacy of the regimen allowed the strain to survive and, over time, develop resistances to other drugs.

The authors recorded the development of resistance to seven drugs in just over a decade in one strain of M. tuberculosis. There are very few treatment options for patients infected with XDR TB. For the most part, patients are given drugs that had been used to treat tuberculosis but which were abandoned when today's first-line drugs became available. The older drugs were abandoned because they were less effective or more toxic.

The authors call for an increased use of drug resistance surveillance programs to help forestall the development of drug-resistance in M. tuberculosis.

Infectious Diseases Society of America



Related Tuberculosis Current Events and Tuberculosis News Articles Tuberculosis Current Events and Tuberculosis News RSS Tuberculosis Current Events and Tuberculosis News RSS
Study reveals why certain drug combinations backfire
Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.

U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.

There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."

Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.

Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

Scientists take step toward simple and portable tuberculosis tests for developing world
Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years.

High mortality rates may explain small body size
A new study suggests that high mortality rates in small-bodied people, commonly known as pygmies, may be part of the reason for their small stature.
More Tuberculosis Current Events and Tuberculosis News Articles
The White Plague: Tuberculosis, Man and Society

The White Plague: Tuberculosis, Man and Society
by Jean Dubos (Author)



Tuberculosis: A Comprehensive Clinical Reference

Tuberculosis: A Comprehensive Clinical Reference
by H. Simon Schaaf MBChB(Stellenbosch) MMed Paed(Stellenbosch) DCM(Stellenbosch) MD Paed(Stellenbosch) (Editor), Alimuddin I. Zumla BSc MBChB MSc PhD(Lond) FRCP(Lond) FRCP(Edin) (Editor)

This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage includes which patient populations face an elevated risk of infection, as well as which therapies are appropriate and how to correctly monitor ongoing treatment so that patients are cured. Properly administer screening tests, interpret their results, and identify manifestations of the disease, with authoritative guidance from expert clinicians from around the world.

Discusses screening tests for tuberculosis so you can interpret their results and identify not only common manifestations of the disease, but also those that are comparatively rare-such as tuberculosis in pregnant women.
Covers all clinical aspects of tuberculosis...

The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost

The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost
by Frank Ryan (Author)

Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of photos.

Tuberculosis (TUBERCULOSIS ( ROM))

Tuberculosis (TUBERCULOSIS ( ROM))
by William N Rom (Editor), Stuart M Garay (Editor)

New York Univ., NY. Summarizes the current advances in tuberculosis and discusses the pathology and pathogenesis of the disease. Also covers complications and treatment options. Chapters include history and epidemiology, genomics and microbiology, host response, therapy, and prevention and control. Previous edition: c1996. DNLM: Tuberculosis--Pulmonary.

Captain of Death: The Story of Tuberculosis

Captain of Death: The Story of Tuberculosis
by Thomas M. Daniel (Author)

The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public health hazard has focused much attention on this ancient disease. This book offers a comprehensive account of the disease from prehistoric times through to the present day, detailing the attempts to eradicate it completely. Its four separate sections (the spread of tuberculosis; its infectious nature; susceptibility to it; and methods of treatment) are linked through the device of presenting...

The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease

The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease
by CHARLOTTE ROBERTS (Author), JANE BUIKSTRA (Author)

Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.

Handbook of Tuberculosis

Handbook of Tuberculosis
by Stefan H. E. Kaufmann (Editor), Paul van Helden (Editor), Eric Rubin (Editor), Warwick J. Britton (Editor)

Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. 

Dr. Stefan Kaufmann, the Founding Director of the Max Planck Institute for Infection Biology in Berlin and Professor of Microbiology and Immunology at the Charité at the Humboldt University, Berlin, has published more than 600 scientific articles and currently serves as President of the European Federation of Immunological Societies and Chair of the Immunology Division of the American...

Historic Tuberculosis Films DVD: History of Pulmonary & Mycobacterium TB & Lung Disease Films

Historic Tuberculosis Films DVD: History of Pulmonary & Mycobacterium TB & Lung Disease Films

Table of Contents: Tuberculosis (1955)11 minutes - This is a fun little film that shows a general history and overview of the effects of tuberculosis on our society. / On the Firing Line (1936) 20 minutes - A fantastic film that has great timeless statistics as well as footage and information about the fight against tuberculosis by the National Tuberculosis Association. / You are the Switchman (1951) 12 minutes running time - A film about noticing the warning signs of cancer and taking appropriate preventative action. You Are the Switchman was a groundbreaking video because it was released two years before the link between smoking cigarettes and cancer was officially out in the open. / City of Hope (1930s) 16 minutes - The Los Angeles Tuberculosis Sanatorium produced this film in the...

The Return of the White Plague: Global Poverty and the 'New' Tuberculosis

The Return of the White Plague: Global Poverty and the 'New' Tuberculosis
by Matthew Gandy (Editor), Alimuddin Zumla (Editor)

The dramatic increase since the 1980s in the global prevalence of tuberculosis, a disease destined as recently as thirty years ago for complete eradication, is a story of medical failure. A pandemic whose geography defies simple categorization—it ranges from schools in the UK to prisons in Russia, from refugee camps in central Africa to affluent suburbs in North America—the 'new' tuberculosis is derived from a combination of different developments such as collapsing health-care services, shifting patterns of poverty and inequality, the spread of HIV, and the emergence of virulent drug-resistant strains.

This collection provides an international survey of current thought on the spread and control of tuberculosis, covering historical, social, political, and medical aspects. While...

Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History

Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History
by Sheila M. Rothman (Author)

For more than 150 years, until well into the twentieth century, tuberculosis was the dreaded scourge that AIDS is for us today. Based on the diaries and letters of hundreds of individuals over five generations, Living in the Shadow of Death is the first book to present an intimate and evocative portrait of what it was like for patients as well as families and communities to struggle against this dreaded disease. "Consumption", as it used to be called, is one of the oldest known diseases. But it wasn't until the beginning of the nineteenth century that it became pervasive and feared in the United States, the cause of one out of every five deaths. Consumption crossed all boundaries of geography and social class. How did people afflicted with the disease deal with their fate? How did their...

© 2009 BrightSurf.com